医学
粪便潜血
癌症筛查
心理干预
家庭医学
乳腺摄影术
癌症预防
考试(生物学)
预防保健
癌症
巴氏试验
梅德林
医疗保健
系统回顾
结直肠癌
乳腺癌
宫颈癌
宫颈癌筛查
护理部
结肠镜检查
公共卫生
内科学
法学
经济
古生物学
生物
经济增长
政治学
作者
Suvi Rintala,Kristina R. Dahlstrom,Eduardo L. Franco,Karolina Louvanto
标识
DOI:10.1016/j.ypmed.2022.107395
摘要
The goal of cancer screening guidelines is to inform health practitioners to practice evidence-based cancer prevention. Cancer screening aims to detect treatable precancerous lesions or early-stage disease to enable actions aimed at decreasing morbidity and mortality. Continuous assessment of the available evidence for or against screening interventions by various organizations often results in conflicting recommendations and create challenges for providers and policymakers. Here we have summarized the current cancer screening recommendations by five leading organizations in North America and Europe: the National Cancer Institute's Physician Data Query (PDQ), the U.S. Preventive Services Task Force (USPSTF), the Canadian Task Force on Preventive Health Care (CTFPHC), the Cochrane Database of Systematic Reviews (CDSR), and the UK National Screening Committee for the National Health Service (UK NSC). All organizations assess evidence based on strength, quality, and quantity, and recommendations are similar although with differences with respect to screening start and stop ages. Recommendations are consistent for colorectal cancer screening with fecal occult blood test or fecal immunochemical test, cervical cancer screening with Pap-test, HPV-test, or co-testing, and breast cancer screening with mammography. However, guidelines vary with respect to age to start and end screening and testing frequency. Tests that have proven to be inefficient or whose use is capable of causing harm are routinely recommended against. Continuous review of screening guidelines is necessary to evaluate the many promising screening tests currently under investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI